Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge.
Vaccine
; 25(52): 8702-6, 2007 Dec 17.
Article
em En
| MEDLINE
| ID: mdl-18035455
ABSTRACT
Although often requiring the development of efficient adjuvants, needle-free mucosal delivery of vaccine is of major interest as a strategy of mass immunization against infectious diseases. We report that mucosal immunization against tetanus toxoid through nasal route, together with active cytotoxic necrotizing factor 1 (CNF1), elicits a specific and long lasting anti-tetanus toxin response, comprising seric IgG and IgA, as well as mucosal IgA. Immunized mice were protected against a challenge with lethal doses of tetanus toxin (10 x LD(50)). The Rho GTPase activating toxin CNF1 is thus an attractive mucosal adjuvant candidate for nasal vaccines.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Tétano
/
Toxinas Bacterianas
/
Toxoide Tetânico
/
Adjuvantes Imunológicos
/
Proteínas de Escherichia coli
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article